InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,571.22
(
0.07%
)
US TECH 100
19,829.60
(
-0.08%
)
Dow Jones
39,526.04
(
0.38%
)
Brent Oil
86.00
(
-0.58%
)
Bitcoin
56,122.54
(
0.49%
)
Post# of 252509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Mpower

Send PM Follow Ignore
Followers 2
Posts 635
Boards Moderated 0
Alias Born 04/23/2007

Mpower

Re: DewDiligence post# 112163

Friday, 01/07/2011 2:38:30 PM

Friday, January 07, 2011 2:38:30 PM

Post# of 252509
In all fairness, Provenge requires minimal additional costs related to supportive care/premedication, unlike many other cancer drugs.

Considering Provenge's ability to extend survival by 4.1 months, the drug costs about $23,000 per month of survival, which is similar to Taxotere (when you take into account supportive care/premedication).
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up